The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$3000
Standard Price
Members save $5
It’s been eight years since the AABB-CAP-ACOG working party first recommended RHD genotyping for patients with weak D phenotypes; how are we doing, and what are we finding? This session will discuss the identification of weak D phenotypes in manual and automated patient test methods and synthesize lessons learned from genotyping weak D phenotypes found among over a million patients in the US and Canada in published series. We will describe the current American status of RHD genotyping services, how serological and molecular methods influence the RHD genotyping findings, what are the most frequent partial RHD variants seen in these patients, and what is known about their risk for allo-anti-D. If you and your care providers have questions about weak D phenotypes, when to obtain genotyping, and what the genotypes mean, we’ll provide answers in an efficient interactive format geared to practical application.
Learning Objectives
Identify manual and automated weak D serological criteria for obtaining RHD genotyping
Discuss the influences of serological methods, genotyping techniques and patient race/ethnicities on RHD genotyping results
Describe which weak partial RHD variants are at most risk for anti-D formation
Review how to apply RHD genotyping results to Rh Immune Globulin therapy and RhD-negative transfusions
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
Join us for an essential panel discussion on cybersecurity in healthcare, where real-world insights and expert analysis come together to enhance your organization's defenses. This session features three distinguished speakers from hospitals and blood centers that have faced cybersecurity attacks…
In today’s rapidly evolving healthcare environment, understanding the latest policy developments is crucial for strategic planning and operational success. This session will explore the significant implications of the recent Supreme Court decision – Loper Bright Enterprises v…
Many blood operators around the world are implementing individualized donor assessments that welcome more trans, non-binary, and gender-diverse people to donate…